Sign in
BOLD Stock Price, Chart, Stats & News
Boundless Bio, Inc.
Save
57.51M
Market cap
–
Current P/E
–
Forward P/E
BOLD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -37.05% |
ROE | -49.73% |
D/E | 0.50x |
Interest coverage ratio | – |
BOLD valuation
P/E | – |
P/S | – |
P/B | 0.25x |
P/CF | -0.53x |
P/FCF | -0.53x |
P/OCF | -0.53x |
PEG | -0.05x |
EV multiple | 0.11x |
About
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Similar securities
Based on sector and market capitalization
Report issue